Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Large Growth in Short Interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 138,600 shares, a growth of 34.8% from the November 15th total of 102,800 shares. Based on an average daily trading volume, of 4,269,100 shares, the short-interest ratio is currently 0.0 days.

Bayer Aktiengesellschaft Trading Down 1.3 %

BAYRY traded down $0.07 on Friday, hitting $5.16. The company had a trading volume of 896,226 shares, compared to its average volume of 1,400,476. The company has a quick ratio of 0.81, a current ratio of 1.32 and a debt-to-equity ratio of 1.19. The company’s fifty day moving average price is $6.16 and its 200 day moving average price is $7.04. Bayer Aktiengesellschaft has a 1-year low of $4.94 and a 1-year high of $9.79.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.10). The firm had revenue of $10.96 billion for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. Equities analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.